Sun Pharma reports 10.5 percent rise in Q2 profit
Bengaluru: Sun Pharmaceutical Industries Ltd, India's largest drugmaker, on Tuesday reported a surprise 10.5 percent rise in second-quarter profit led by a surge in sales of speciality drugs.Consolidated net profit for three months ended Sept. 30 was 22.62 billion Indian rupees ($273.75 million), up from 20.47 billion rupees last year, said in an exchange filing.Analysts, on average, expected...
Login or Register to read the full article
Bengaluru: Sun Pharmaceutical Industries Ltd, India's largest drugmaker, on Tuesday reported a surprise 10.5 percent rise in second-quarter profit led by a surge in sales of speciality drugs.
Consolidated net profit for three months ended Sept. 30 was 22.62 billion Indian rupees ($273.75 million), up from 20.47 billion rupees last year, said in an exchange filing.
Analysts, on average, expected the company to report a profit of 19.83 billion rupees, according to Refinitiv IBES data.
Total revenue from operations jumped 14 percent 109.52 billion rupees.
Drug sales in India, its biggest market, rose 8.5 percent to 34.60 billion rupees, whereas sales in the United States, its second-biggest market, were at 32.91 billion rupees, up from 26.77 billion rupees.
Sun Pharma's shares rose as much as 3.2 percent to hit over a seven-year high soon after the earnings announcement.
The company, founded in 1983, has its drugs available in more than 100 countries and makes over-the-counter medications, anti-retrovirals, and active pharmaceutical ingredients for chronic and acute treatments.
Meanwhile, the drugmaker has been diversifying from the generic business amid intense price competition, entering the high-margin specialty segment about seven years ago.
Global sales of specialty drugs grew 27.5 percent to over $200 million, driven by psoriasis medication Ilumya, Cequa eye drops and acne treatment Winlevi, Managing Director Dilip Shanghvi said in a statement.
EBITDA margin for the second quarter rose to 27 percent from 26.8 percent in the previous quarter. The margin, however, came in slightly lower from a year ago as input costs grew 27.3 percent to 20.17 billion rupees.
Read also: Sun Pharma Gets CDSCO Panel Nod To Study Elagolix tablet
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd